Stockreport

CytoDyn Anticipates Revenue Commencing in August 2019 from Use of PA-14 and/or PRO 140 in Diagnostic Test

CYTODYN INC  (CYDY) 
NASDAQ:AMEX Investor Relations: ir.cytodyn.com
PDF CytoDyn Signs Non-binding Agreement for Diagnostic Licenseand Supply Agreement with IncellDX for PA-14 and/or PRO 140 (non-commercial grade) Collaboration represents an [Read more]